CDR-Life Presents Precise Tumor and Patient Selection for CD

- CDR404 represents a potential paradigm shift in the development of T-cell engagers for solid cancers - Epithelial cancer indications eligible for CDR404 Phase 1 trial include non-small cell lung carcinoma (NSCLC), head & neck squamous cell carcinoma and bladder cancer ZÜRICH, Switzerland, Oct. 23, 2023 (GLOBE NEWSWIRE) -- CDR-Life Inc. presented findings on tumor target expression and precise patient selection for the upcoming Phase 1 trial of CDR404 (Abstract 200P), a first-of-its-kind bispec

Related Keywords

Spain , Madrid , Switzerland , United States , Emiliano Calvo , Swethajit Biswas , Globe Newswire Inc , Cancer Genome Atlas , Senior Investigator , Chief Medical Officer , Presentation Details , Precise Tumor , Patient Selection , Squamous Cell Carcinoma , Lung Adenocarcinoma , Bladder Cancer , Rna Expression , Solid Tumors , Bladder Cancers , Expression Levels , Phase 1 Trial , Tumor Types ,